Tirzepatide showed greater 3-month real-world weight loss than semaglutide in adults with obesity

Obesity is a complex chronic disease requiring effective management beyond lifestyle modifications. While GLP-1 receptor agonists (like semaglutide) and GLP-1/GIP receptor co-agonists (like tirzepatide) have demonstrated significant weight loss in clinical trials, real-world comparative evidence on their early efficacy is scarce. Specifically, data on longitudinal body-weight changes in diverse populations with irregular follow-up, which better reflects clinical practice, is needed. This study addresses the gap in understanding how these powerful incretin-based therapies perform head-to-head in a real-world setting, informing practical treatment strategies.

Written by TitrateLab, separately from the study summarized above.